
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus is a promising company with positive growth prospects in the medical aesthetics market, as reflected in its strong Q4 performance with over 600 new accounts and a stable reorder rate. With the launch of Evolysse and the initiation of a large sampling and experience program in Q2, the company is well-positioned to further drive revenue growth. With a healthy balance sheet and access to additional debt, Evolus has the financial flexibility to support its expansion plans. While there are risks such as consumer spending environment and potential regulatory delays, the company's strong product portfolio and growth potential make it a Buy with a $13 price target based on 2.5x 12-24 month sales estimate.
Bears say
Evolus is facing increased competition in the medical aesthetics market, particularly with the launch of its competitor's Voluma and the expected launch of its "Sculpt" filler in 2027. While the company has experienced steady growth in its Jeuveau purchasing accounts and the introduction of Evolysse filler has allowed for product bundling, the company has lower growth expectations for its Evolysse Form and Smooth products. Additionally, the company has faced margin pressure due to product and geography mix shift, offset by expense control. While the company expects to achieve positive adjusted operating income in 2026 and reach adjusted operating income margins of 13%-15% in 2028, there are concerns for sustained growth and profitability in future years.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares